Company news
Pathkey.ai Limited (ASX:PKY) news
Pathkey.ai Limited news releases on 6ix. Latest, Sep 10, 2026: Leading Chip Designer & AI Expert Appointed Advisory Board
Press releases & updates
Leading Chip Designer & AI Expert Appointed Advisory Board
September 9, 2026
Appendix 4E
August 31, 2026
PKY Appoints Ex-Altium Chairman Sam Weiss & Raises $2.8M
August 11, 2026
INTURAI SIGNS WITH ASX-LISTED PATHKEY TO ADVANCE DRONE SWARM COMMAND AND CONTROL ON AI EDGE
July 15, 2026
Chipforge Presentation
June 23, 2026
PKY Appoints AI Systems and Defence Technology Leader as CEO
May 10, 2026
Response to ASX Price Query
April 29, 2026
PKY to Acquire AI Semiconductor Design Verification Platform
April 28, 2026
PKY Secures Key Commercial Contract with Imunexus
April 1, 2026
PKY - Appendix 4D & Half Year Results
February 26, 2026
Response to ASX Price and Volume Query
February 18, 2026
Quarterly Activities & Cashflow Report
January 30, 2026
Offer Document
December 4, 2025
PKY Completes $2.5m Placement and Launches Rights Issue
November 26, 2025
Trading Halt
November 24, 2025
Pathkey.AI and Armstrong Clinical Partner on AI Trials
November 11, 2025
TrialKeys AI Predictions Continue to Outperform
October 8, 2025
Pathkey Advances TrialKey with Drug-Level AI Features
September 17, 2025
Successful TrialKey Observational Predictions
September 7, 2025
Preliminary Financial Report - 30 June 2025
August 28, 2025
Opyl Signs Service Agreement with Innovatrix
August 11, 2025
Treasury Update
June 25, 2025
OPL & Innovatrix to Launch Clinical Trial Insurance Product
June 18, 2025
OPL Deepens Global AI Collaborations - Cardialysis & Evestia
June 11, 2025
OPL Completes Strategic Review
June 9, 2025
Completion of $1.5m Oversubscribed Placement
May 1, 2025
OPL - Appendix 4D & Half Year Results
February 27, 2025
Opyl Announces Partnership with Avion
February 7, 2025
OPL Signs Landmark JV with X Firm Ltd
January 6, 2025
OPL Signs Partnership Agreement with NeuOrphan
December 10, 2024
OPL Partners L39 Capital to Launch AI-Powered Biotech Fund
December 9, 2024
OPL Signs Service Agreement with Southern CDC
November 20, 2024
Updated Quarterly Activities & Cashflow Report
October 29, 2024
Opyl Signs New Service Agreement with Commercial Eyes
October 15, 2024
Opyl Signs New Service Agreement with Biointelect
September 24, 2024
Strategic Partnership with Phenix Health Compendium Platform
September 22, 2024
Opyl Enters Strategic Partnership with Alithia Life Sciences
September 16, 2024
Opyl - Full Year Results
August 29, 2024
Opyl - Appendix 4E
August 29, 2024
Opyl Secures $700K loans to advance TrialKey & Drive Growth
August 21, 2024
Opyl - Business Update & Appendix 4C
July 30, 2024
OPL signs MOU for EMEA & US Expansion
July 23, 2024
Opyl Partners with L39 Capital to Launch AI Biotech Fund
July 8, 2024
Opyl Announces First Trial Gen Revenue & Customer
June 5, 2024
Opyl signs binding agreement for sale of Opin business
April 22, 2024
Reinstatement to Quotation
March 22, 2024
Opyl receives non-binding offer for its Opin business
March 22, 2024
Suspension from Quotation
March 21, 2024
Request for Trading Halt
March 20, 2024
Pause in Trading
March 20, 2024